(Reuters) – Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech listing this year.
Maze priced the offering at $16 per share, within its indicated range of $15 to $17.
(Reporting by Ateev Bhandari and Rishabh Jaiswal in Bengaluru; Editing by Sherry Jacob-Phillips)
Comments